OPDIVO® approved by FDA once again

OPDIVO® approved by FDA once again

On the 17th of August 2018, the US FDA approved a new indication for Opdivo® (nivolumab). This time, Opdivo® has been approved for the treatment of patients with metastatic small cell lung cancer (SCLC) whose cancer has progressed after platinum-based chemotherapy and at least one other line of therapy.

Read more

Previous

Next